Literature DB >> 34471956

Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study.

Jung-Hyun Park1, Sura Cho1, Sun-Jong Kim1, Tae-Dong Jeong2, Yeung-Chul Mun3, Jin-Woo Kim4.   

Abstract

In this prospective study, serum levels of 12 possible biomarkers were compared between osteonecrosis of the jaw (ONJ) and control groups, before and after dentoalveolar surgery. The results suggest that patients with abnormal serum levels of specific biomarkers should be monitored closely for the prevention and early diagnosis of ONJ.
INTRODUCTION: Bisphosphonate-related osteonecrosis of the jaw (ONJ) is an adverse effect of long-term bisphosphonate therapy. This study aimed to identify bone biomarkers for ONJ risk assessment and diagnosis.
METHODS: This prospective study included patients with histories of bisphosphonate therapy without current ONJ who were in need of dentoalveolar surgery of the jaw area. Serum levels of 12 possible bone markers, selected based on their involvement in ONJ pathogenesis, were compared between ONJ and control groups before dentoalveolar surgery (T0), at 8 postoperative weeks (T1), and at 4 months after diagnosis(T2).
RESULTS: Seventy-six patients who met the inclusion criteria were included in the study; 33 were assigned to the ONJ group, and 43 patients without ONJ signs or symptoms after dentoalveolar surgery were assigned to the control group. In the ONJ group, at both T0 and T1, the mean tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) levels were significantly lower and the mean Dickkopf-related protein 1 (DKK1) levels were significantly higher than the corresponding values for the control group. Linear mixed model analysis revealed significant group effects over time for serum TRACP 5b and DKK1 after adjusting for demographic, pharmacological, and diagnostic variables. Lower serum levels of TRACP 5b under a specified cut-off value (≤ 2.899 U/L) at T0 indicated a 20.40-fold increased risk of ONJ development.
CONCLUSION: Patients with abnormally low serum levels of TRACP 5b and high serum levels of DKK1 should be monitored closely before and after dentoalveolar surgery for the prevention and early diagnosis of ONJ.
© 2021. International Osteoporosis Foundation and National Osteoporosis Foundation.

Entities:  

Keywords:  Biomarker; Bisphosphonate; Dickkopf-related protein 1; Osteonecrosis of the jaw; Tartrate-resistant acid phosphatase isoform 5b

Mesh:

Substances:

Year:  2021        PMID: 34471956     DOI: 10.1007/s00198-021-06137-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   5.071


  37 in total

Review 1.  Osteoclast-derived activity in the coupling of bone formation to resorption.

Authors:  T John Martin; Natalie A Sims
Journal:  Trends Mol Med       Date:  2005-02       Impact factor: 11.951

Review 2.  Are nonresorbing osteoclasts sources of bone anabolic activity?

Authors:  Morten A Karsdal; Thomas J Martin; Jens Bollerslev; Claus Christiansen; Kim Henriksen
Journal:  J Bone Miner Res       Date:  2007-04       Impact factor: 6.741

3.  Association between biomarkers and medication-related osteonecrosis of the jaws: a systematic review.

Authors:  Vittorio Moraschini; Daniel Costa Ferreira de Almeida; Carlos Marcelo Figueredo; Monica Diuana Calasans-Maia
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2019-02-26

4.  Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone.

Authors:  Amy J Koh; Burak Demiralp; Kathleen G Neiva; Joanna Hooten; Rahime M Nohutcu; Hyunsuk Shim; Nabanita S Datta; Russell S Taichman; Laurie K McCauley
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

Review 5.  A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution.

Authors:  Gayathri Subramanian; Harold V Cohen; Samuel Y P Quek
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2011-08-06

6.  Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption.

Authors:  Morten A Karsdal; Kim Henriksen; Mette G Sørensen; Jeppe Gram; Sophie Schaller; Morten H Dziegiel; Anne-Marie Heegaard; Palle Christophersen; Thomas J Martin; Claus Christiansen; Jens Bollerslev
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

Review 7.  Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases.

Authors:  K Henriksen; L B Tanko; P Qvist; P D Delmas; C Christiansen; M A Karsdal
Journal:  Osteoporos Int       Date:  2006-11-24       Impact factor: 4.507

Review 8.  Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone.

Authors:  Serge Cremers; Azeez Farooki
Journal:  Ann N Y Acad Sci       Date:  2010-09-29       Impact factor: 5.691

Review 9.  Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.

Authors:  Mohamed E Awad; Christina Sun; Joshua Jernigan; Mohammed Elsalanty
Journal:  J Am Dent Assoc       Date:  2019-06-28       Impact factor: 3.634

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

View more
  2 in total

1.  Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.

Authors:  Jin-Woo Kim; Mi Kyung Kwak; Jeong Joon Han; Sung-Tak Lee; Ha Young Kim; Se Hwa Kim; Junho Jung; Jeong Keun Lee; Young-Kyun Lee; Yong-Dae Kwon; Deog-Yoon Kim
Journal:  J Bone Metab       Date:  2021-11-30

Review 2.  Oral Complications in Cancer Patients-Medication-Related Osteonecrosis of the Jaw (MRONJ).

Authors:  Cesar Augusto Migliorati
Journal:  Front Oral Health       Date:  2022-04-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.